Business
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
BOSTON & MONTREAL, May 07, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without concomitant papillary disea
About this update from Engene Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/733177ec5a9b9716525807e9bf93c86e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bgPGwZRU087p_BuVeDAOOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/733177ec5a9b9716525807e9bf93c86e","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/6mzh0D4oYK8rDqRx9AIfdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/733177ec5a9b9716525807e9bf93c86e","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ccnroC7dfPE3STZCf_2W2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/733177ec5a9b9716525807e9bf93c86e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"54% complete response (CR) rate at any time; 43% six‑month CR rate ","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"Low rate of progression to muscle-invasive or higher disease (3.2%) ","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%) ","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"Kaplan-Meier estimate of 12-month CR rate is 25%","length":48,"tagName":"p","attribs":{}},{"type":"text","content":"enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m. ET","length":77,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON & MONTREAL, May 07, 2026--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without concomita...